169 related articles for article (PubMed ID: 33362379)
1. Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.
Takaya H; Namisaki T; Moriya K; Shimozato N; Kaji K; Ogawa H; Ishida K; Tsuji Y; Kaya D; Takagi H; Fujinaga Y; Nishimura N; Sawada Y; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
World J Gastroenterol; 2020 Dec; 26(45):7232-7241. PubMed ID: 33362379
[TBL] [Abstract][Full Text] [Related]
2. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.
Takaya H; Namisaki T; Shimozato N; Kaji K; Kitade M; Moriya K; Sato S; Kawaratani H; Akahane T; Matsumoto M; Yoshiji H
World J Gastrointest Oncol; 2019 May; 11(5):424-435. PubMed ID: 31139312
[TBL] [Abstract][Full Text] [Related]
3. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
[TBL] [Abstract][Full Text] [Related]
4. VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.
Asada S; Namisaki T; Kaji K; Takaya H; Kubo T; Akahane T; Kawaratani H; Nishimura N; Takeda S; Masuda H; Shibamoto A; Inoue T; Iwai S; Tomooka F; Tsuji Y; Fujinaga Y; Kitagawa K; Mitoro A; Sato S; Matsumoto M; Yoshiji H
Dig Dis Sci; 2024 Mar; 69(3):851-869. PubMed ID: 38244124
[TBL] [Abstract][Full Text] [Related]
5. The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure.
Takaya H; Namisaki T; Enomoto M; Kubo T; Tsuji Y; Fujinaga Y; Nishimura N; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829443
[TBL] [Abstract][Full Text] [Related]
6. Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis.
Enomoto M; Takaya H; Namisaki T; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Inoue T; Matsumoto M; Yoshiji H
Hepatol Res; 2022 Apr; 52(4):390-400. PubMed ID: 34964539
[TBL] [Abstract][Full Text] [Related]
7. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.
Tsujii N; Nogami K; Matsumoto M; Yoshizawa H; Takase T; Tanaka I; Sakai T; Fukuda K; Hayakawa M; Sakai K; Isonishi A; Matsuura K; Fujimura Y; Shima M
Thromb Res; 2019 Jul; 179():1-10. PubMed ID: 31055186
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.
Xu X; Feng Y; Jia Y; Zhang X; Li L; Bai X; Jiao L
Thromb Res; 2022 Oct; 218():83-98. PubMed ID: 36027630
[TBL] [Abstract][Full Text] [Related]
10. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
[TBL] [Abstract][Full Text] [Related]
11. ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.
Takaya H; Namisaki T; Asada S; Iwai S; Kubo T; Suzuki J; Enomoto M; Tsuji Y; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407443
[TBL] [Abstract][Full Text] [Related]
12. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
[TBL] [Abstract][Full Text] [Related]
13. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Niizeki T; Sumie S; Torimura T; Kurogi J; Kuromatsu R; Iwamoto H; Aino H; Nakano M; Kawaguchi A; Kakuma T; Sata M
J Gastroenterol; 2012 Jun; 47(6):686-95. PubMed ID: 22382631
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.
Takaya H; Kawaratani H; Tsuji Y; Nakanishi K; Saikawa S; Sato S; Sawada Y; Kaji K; Okura Y; Shimozato N; Kitade M; Akahane T; Moriya K; Namisaki T; Mitoro A; Matsumoto M; Fukui H; Yoshiji H
United European Gastroenterol J; 2018 Nov; 6(9):1401-1409. PubMed ID: 30386613
[TBL] [Abstract][Full Text] [Related]
15. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
16. Elevated ADAMTS13 Activity is Associated with Poor Postoperative Outcome in Patients Undergoing Liver Resection.
Haegele S; Fuxsteiner J; Pereyra D; Koeditz C; Rumpf B; Schuetz C; Schwarz C; Brostjan C; Gruenberger T; Starlinger P
Sci Rep; 2018 Nov; 8(1):16823. PubMed ID: 30429491
[TBL] [Abstract][Full Text] [Related]
17. von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
Murphy SJX; Lim ST; Hickey F; Kinsella JA; Smith DR; Tierney S; Egan B; Feeley TM; Murphy SM; Collins DR; Coughlan T; O'Neill D; Harbison JA; Madhavan P; O'Neill SM; Colgan MP; O'Donnell JS; O'Sullivan JM; Hamilton G; McCabe DJH
Thromb Haemost; 2021 Jan; 121(1):86-97. PubMed ID: 32932544
[TBL] [Abstract][Full Text] [Related]
18. Evaluating von Willebrand factor and ADAMTS13 levels in thalassemia major patients and assessing a possible association with Thrombospondin-1.
Al-Sabaan K; Al-Awadhi A
Int J Lab Hematol; 2023 Dec; 45(6):945-952. PubMed ID: 37438087
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.
Qu L; Jiang M; Qiu W; Lu S; Zhao Y; Xia L; Ruan C; Zhao Y
Clin Appl Thromb Hemost; 2016 Apr; 22(3):252-9. PubMed ID: 25916953
[TBL] [Abstract][Full Text] [Related]
20. Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.
Takaya H; Kawaratani H; Kubo T; Seki K; Sawada Y; Kaji K; Okura Y; Takeda K; Kitade M; Moriya K; Namisaki T; Mitoro A; Matsumoto M; Fukui H; Yoshiji H
Hepatol Res; 2018 Feb; 48(3):E52-E60. PubMed ID: 28628948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
